PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Commends Millipores Success in Developing the Enhanced Mammalian Gene Expression UCOE Technology - Millipore Corporation's Ubiquitous Chromatin Opening Element (UCOE™) gene expression technology as the recipient of the 2007 Frost & Sullivan Technology Innovation of the Year Award in the U.S. Drug Discovery Technologies market (NYSE: MIL)
Frost & Sullivan Commends Millipores Success in Developing the Enhanced Mammalian Gene Expression UCOE Technology

 

NewswireToday - /newswire/ - Palo Alto, CA, United States, 2007/12/06 - Millipore Corporation's Ubiquitous Chromatin Opening Element (UCOE™) gene expression technology as the recipient of the 2007 Frost & Sullivan Technology Innovation of the Year Award in the U.S. Drug Discovery Technologies market (NYSE: MIL).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Frost & Sullivan selects Millipore Corporation's Ubiquitous Chromatin Opening Element (UCOE™) gene expression technology as the recipient of the 2007 Frost & Sullivan Technology Innovation of the Year Award in the U.S. Drug Discovery Technologies market.

Millipore's approach for mammalian gene and protein expression offers significant benefits to manufacturers of biologic-based medicines, as there is high demand for these drugs because they are required for patients diagnosed with cancer and other diseases.

The UCOE™ technology exploits the principles guiding the expression of housekeeping genes, primarily their constitutively active state, in order to have high expression of transgenes that have been incorporated into a cell's genome.

Due to the responsibility to maintain the cellular environment, housekeeping genes are endowed with a chromatin region that is always open to the cell's translation machinery, and the UCOE technology uses a novel approach that harnesses these key regulatory DNA elements associated with the housekeeping genes to perform a similar function when incorporated with proprietary expression vectors.

Because of its chromatin-localization-independent high level expression, UCOE™ technology aids isolation of highly productive clonal lines by screening nearly 100 clones in less than four months, which is significantly faster than the gene amplification-based program of conventional technologies that requires as much as 12-15 months. The cell lines generated with UCOE™ are stable for at least 130 generations, which roughly corresponds to 130 days for CHO cells.

"Overall, protein expression levels are shown to be 10-50 fold higher when using Millipore's UCOE technology then those obtained through conventional mammalian protein expression methods," says Frost & Sullivan Industry Analyst Shankar Sellappan, Ph.D. "These elevated expression levels are achieved by significantly higher specific productivity rates resulting from robust transcriptional activity in UCOE™-controlled transcriptionally unrestricted chromatin sites."

A significant advantage of the UCOE™ technology is that it catalyzes increased yields of recombinant proteins from both pools and clones, and enables production of gram-level quantities of protein from stable pools in less than two months. This allows for effortless generation of research material early on during a drug developmental program, and supports the toxicology study efforts that can be performed in parallel, saving time and costs.

"Having established itself as a leader in separations methodologies, Millipore has successfully entered the growing market for protein expression products in the biopharmaceutical industry," notes Dr. Sellappan. "Millipore's innovative approach dramatically improves the quality of research, while its UCOE™ technology is expected to have a lasting impact on both drug discovery efforts and the development and manufacturing of therapeutic drugs."

Millipore continues to refine the UCOE™ technology by improving the vector architecture in order to provide a more efficient and robust transcriptional and translational performance.

Each year Frost & Sullivan presents this Award to the company that has demonstrated technological superiority within its industry. This award recognizes the ability of the company to successfully develop and introduce new technology, formulate a well-designed product family, and make significant product performance contributions to the industry.

Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Millipore
Millipore (NYSE: MIL) is a Life Science leader providing cutting-edge technologies, tools, and services for bioscience research and biopharmaceutical manufacturing. As a strategic partner, we collaborate with customers to confront the world's challenging human health issues. From research to development to production, our scientific expertise and innovative solutions help customers tackle their most complex problems and achieve their goals. Millipore Corporation is an S&P 500 company with more than 6,100 employees in 47 countries worldwide.

About Frost & Sullivan
Frost & Sullivan, the Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Commends Millipores Success in Developing the Enhanced Mammalian Gene Expression UCOE Technology

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Melina Trevino 
210.247.2420 Melina.trevino[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution
PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)